CN Patent

CN105378085A — 用于调节hbv和ttr表达的组合物和方法

Assigned to GlaxoSmithKline LLC · Expires 2016-03-02 · 10y expired

What this patent protects

本文提供了具有缀合物基团的低聚化合物。在某些实施方案中，所述低聚化合物缀合至N-乙酰基半乳糖胺。

USPTO Abstract

本文提供了具有缀合物基团的低聚化合物。在某些实施方案中，所述低聚化合物缀合至N-乙酰基半乳糖胺。

Drugs covered by this patent

eplontersen-sodium (EPLONTERSEN SODIUM)

Patent Metadata

Patent number: CN105378085A
Jurisdiction: CN
Classification: —
Expires: 2016-03-02
Drug substance claim: No
Drug product claim: No
Assignee: GlaxoSmithKline LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.